Phase 1b study of the MDM2 inhibitor AMG 232 with or...

Blood Advances 2019 / 07 Vol. 3; Iss. 13

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia

Erba, Harry P., Becker, Pamela S., Shami, Paul J., Grunwald, Michael R., Flesher, Donna L., Zhu, Min, Rasmussen, Erik, Henary, Haby A., Anderson, Abraham A., Wang, Eunice S.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
3
Journal:
Blood Advances
DOI:
10.1182/bloodadvances.2019030916
Date:
July, 2019
File:
PDF, 1.03 MB
2019
Conversion to is in progress
Conversion to is failed